BASKING RIDGE, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) announced that it raised $2,277,000 through the private placement of its equity securities. These securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration under such Act or an applicable exemption from the registration requirements. Millennium, through its wholly owned subsidiary, Millennium Biotechnologies, Inc., is now positioned to launch products into the P4 Healthcare oncology network and the U.S. and International sports markets.
The recently announced P4 Healthcare relationship is an unprecedented approach to nutrition in the medical markets. Many of the largest private oncology practices in the country will be preferentially offering RESURGEX(R) products to their patients, in their offices, beginning in Q4 of '07. In addition, the Resurgex line of products will be strategically marketed by P4 in its professional Caring4Cancer journal and informative website, http://www.caring4cancer.com
After several successful clinical trials, Millennium will launch its new sports product SURGEX(TM) into the U.S. and International sports markets in Q4 of '07. The response to the results of the trials as well as feedback on SURGEX(TM) from many professional strength and conditioning coaches and players, has been overwhelmingly positive, and sets the stage for a national and international launch.
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies,
Inc. is a research-based nutraceutical company and a pioneer in the
emerging field of specialized nutritional supplements. The company's
flagship products, Resurgex(R), Resurgex Plus(R), and Resurgex Select(R),
are designed to assist in reducing fatigue and oxidative stress,
maintaining lean muscle and immune support in immunocompromi
|SOURCE Millennium Biotechnologies Group, Inc.|
Copyright©2007 PR Newswire.
All rights reserved